{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:36:40Z","timestamp":1793043400278,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Korea Health Technology R&D Project","award":["RS-2018-KH049510"],"award-info":[{"award-number":["RS-2018-KH049510"]}]},{"DOI":"10.13039\/501100003569","name":"the Ministry of Food and Drug Safety","doi-asserted-by":"crossref","award":["17172MFDS212"],"award-info":[{"award-number":["17172MFDS212"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51355-8","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:22:28Z","timestamp":1778318548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing Zirconium-89 labeling for chimeric antigen receptor T cell PET imaging by comparing desferrioxamine and oxine"],"prefix":"10.1038","volume":"16","author":[{"given":"Nare","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seog-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunsu","family":"Soh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyori","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Min","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junho","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Jun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sook","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"51355_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv439","volume":"108","author":"H Dai","year":"2016","unstructured":"Dai, H., Wang, Y., Lu, X. & Han, W. Chimeric antigen receptors modified T-cells for cancer therapy. J. Natl. Cancer Inst. 108, djv439. https:\/\/doi.org\/10.1093\/jnci\/djv439 (2016).","journal-title":"J. Natl. Cancer Inst."},{"key":"51355_CR2","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","volume":"21","author":"AK Singh","year":"2020","unstructured":"Singh, A. K. & McGuirk, J. P. CAR T cells: Continuation in a revolution of immunotherapy. Lancet Oncol. 21, e168\u2013e178. https:\/\/doi.org\/10.1016\/S1470-2045(19)30823-X (2020).","journal-title":"Lancet Oncol."},{"key":"51355_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167. https:\/\/doi.org\/10.1038\/s41571-019-0297-y (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"51355_CR4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava, S. & Riddell, S. R. Engineering CAR-T cells: Design concepts. Trends Immunol. 36, 494\u2013502. https:\/\/doi.org\/10.1016\/j.it.2015.06.004 (2015).","journal-title":"Trends Immunol."},{"key":"51355_CR5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fimmu.2019.00456","volume":"10","author":"J Liu","year":"2019","unstructured":"Liu, J., Zhou, G., Zhang, L. & Zhao, Q. Building potent chimeric antigen receptor T cells with CRISPR genome editing. Front Immunol. 10, 456. https:\/\/doi.org\/10.3389\/fimmu.2019.00456 (2019).","journal-title":"Front Immunol."},{"key":"51355_CR6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. U. S. A. 90, 720\u2013724. https:\/\/doi.org\/10.1073\/pnas.90.2.720 (1993).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"51355_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke, F. L. et al. Phase 1 results of ZUMA-1: Q multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25, 285\u2013295. https:\/\/doi.org\/10.1016\/j.ymthe.2016.10.020 (2017).","journal-title":"Mol. Ther."},{"key":"51355_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980 (2019).","journal-title":"N. Engl. J. Med."},{"key":"51355_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866 (2018).","journal-title":"N. Engl. J. Med."},{"key":"51355_CR10","doi-asserted-by":"crossref","unstructured":"\u00a0Wang Z., Wu Z., Liu Y. & Han W. New development in CAR-T cell therapy. J Hematol Oncol 10, 53,\u00a0doi:10.1186\/s13045-017-0423-1 (2017)\u00a0","DOI":"10.1186\/s13045-017-0423-1"},{"key":"51355_CR11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial. Nat. Med. 26, 1569\u20131575. https:\/\/doi.org\/10.1038\/s41591-020-1081-3 (2020).","journal-title":"Nat. Med."},{"key":"51355_CR12","doi-asserted-by":"publisher","first-page":"10266","DOI":"10.1021\/acs.chemrev.1c00767","volume":"122","author":"PJ Gawne","year":"2022","unstructured":"Gawne, P. J. et al. Direct cell radiolabeling for in vivo cell tracking with PET and SPECT imaging. Chem. Rev. 122, 10266\u201310318. https:\/\/doi.org\/10.1021\/acs.chemrev.1c00767 (2022).","journal-title":"Chem. Rev."},{"key":"51355_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nrclinonc.2011.141","volume":"8","author":"MF Kircher","year":"2011","unstructured":"Kircher, M. F., Gambhir, S. S. & Grimm, J. Noninvasive cell-tracking methods. Nat. Rev. Clin. Oncol. 8, 677\u2013688. https:\/\/doi.org\/10.1038\/nrclinonc.2011.141 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"51355_CR14","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.231406","volume":"310","author":"SY Kim","year":"2024","unstructured":"Kim, S. Y. et al. Direct and indirect chimeric antigen receptor T-cell imaging with PET\/MRI in a tumor xenograft model. Radiology 310, e231406. https:\/\/doi.org\/10.1148\/radiol.231406 (2024).","journal-title":"Radiology"},{"key":"51355_CR15","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2967\/jnumed.117.206714","volume":"59","author":"MR Weist","year":"2018","unstructured":"Weist, M. R. et al. PET of adoptively transferred chimeric antigen receptor T cells with (89)Zr-oxine. J. Nucl. Med. 59, 1531\u20131537. https:\/\/doi.org\/10.2967\/jnumed.117.206714 (2018).","journal-title":"J. Nucl. Med."},{"key":"51355_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-015-0098-y","volume":"5","author":"A Bansal","year":"2015","unstructured":"Bansal, A. et al. Novel (89)Zr cell labeling approach for PET-based cell trafficking studies. EJNMMI Res. 5, 19. https:\/\/doi.org\/10.1186\/s13550-015-0098-y (2015).","journal-title":"EJNMMI Res."},{"key":"51355_CR17","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1158\/1078-0432.CCR-19-2897","volume":"26","author":"N Sato","year":"2020","unstructured":"Sato, N. et al. In vivo tracking of adoptively transferred natural killer cells in Rhesus macaques using (89)zirconium-oxine cell labeling and PET imaging. Clin. Cancer Res. 26, 2573\u20132581. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2897 (2020).","journal-title":"Clin. Cancer Res."},{"key":"51355_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01770-z","volume":"11","author":"PS Patrick","year":"2020","unstructured":"Patrick, P. S. et al. Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with (89)Zr-oxine PET-CT. Stem Cell Res. Ther. 11, 256. https:\/\/doi.org\/10.1186\/s13287-020-01770-z (2020).","journal-title":"Stem Cell Res. Ther."},{"key":"51355_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.nucmedbio.2020.09.002","volume":"90\u201391","author":"F Man","year":"2020","unstructured":"Man, F., Khan, A. A., Carrascal-Minino, A., Blower, P. J. & R, T. R. A kit formulation for the preparation of [89Zr]Zr(oxinate)4 for PET cell tracking: White blood cell labelling and comparison with [111In]In(oxinate)3. Nucl. Med. Biol. 90\u201391, 31\u201340. https:\/\/doi.org\/10.1016\/j.nucmedbio.2020.09.002 (2020).","journal-title":"Nucl. Med. Biol."},{"key":"51355_CR20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s11307-021-01622-z","volume":"23","author":"I Friberger","year":"2021","unstructured":"Friberger, I. et al. Optimisation of the synthesis and cell labelling conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: A direct in vitro comparison in cell types with distinct therapeutic applications. Mol. Imaging Biol. 23, 952\u2013962. https:\/\/doi.org\/10.1007\/s11307-021-01622-z (2021).","journal-title":"Mol. Imaging Biol."},{"key":"51355_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1148\/radiol.15142849","volume":"275","author":"N Sato","year":"2015","unstructured":"Sato, N. et al. (89)Zr-oxine complex PET cell imaging in monitoring cell-based therapies. Radiology 275, 490\u2013500. https:\/\/doi.org\/10.1148\/radiol.15142849 (2015).","journal-title":"Radiology"},{"key":"51355_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.nucmedbio.2009.05.007","volume":"36","author":"JP Holland","year":"2009","unstructured":"Holland, J. P., Sheh, Y. & Lewis, J. S. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol. 36, 729\u2013739. https:\/\/doi.org\/10.1016\/j.nucmedbio.2009.05.007 (2009).","journal-title":"Nucl. Med. Biol."},{"key":"51355_CR23","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1021\/acs.bioconjchem.7b00325","volume":"28","author":"S Heskamp","year":"2017","unstructured":"Heskamp, S. et al. (89)Zr-immuno-positron emission tomography in oncology: State-of-the-art (89)Zr radiochemistry. Bioconjug. Chem. 28, 2211\u20132223. https:\/\/doi.org\/10.1021\/acs.bioconjchem.7b00325 (2017).","journal-title":"Bioconjug. Chem."},{"key":"51355_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23030638","volume":"23","author":"NB Bhatt","year":"2018","unstructured":"Bhatt, N. B., Pandya, D. N. & Wadas, T. J. Recent advances in zirconium-89 chelator development. Molecules 23, 638. https:\/\/doi.org\/10.3390\/molecules23030638 (2018).","journal-title":"Molecules"},{"key":"51355_CR25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453\u20131464. https:\/\/doi.org\/10.1038\/mt.2009.83 (2009).","journal-title":"Mol. Ther."},{"key":"51355_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223814","volume":"15","author":"SH Lee","year":"2020","unstructured":"Lee, S. H. et al. Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging. PLoS ONE 15, e0223814. https:\/\/doi.org\/10.1371\/journal.pone.0223814 (2020).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51355-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51355-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51355-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:37:04Z","timestamp":1783553824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51355-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51355"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51355-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21309"}}